{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1877"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1913"}],"units":"Participants"}],"description":"Data from all subjects who received any study drug were included in the analysis. Adverse events were classified using the Medical Dictionary for Regulatory Activities (MedDRA) classification system. A subject having the same event more than once was counted only once. Adverse events were summarized by worst NCI (National Cancer Institute) CTCAE (Common Terminology Criteria for Adverse Events) VERSION 3.0 grade. Incidence was defined as the number of subjects who experienced an adverse event within their period of participation in this study.","groups":[{"description":"This was a multicenter, non-randomized, open-label, uncontrolled, single-arm treatment study of lenalidomide as monotherapy or in combination with dexamethasone in subjects with previously treated relapsed or refractory multiple myeloma, with measurable myeloma paraprotein in serum and/or urine. Subjects who met all of the eligibility criteria were enrolled into the study. Screening procedures took place within 28 days of first dose. Subjects who qualified for participation received oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days.","id":"OG000","title":"Lenalidomide"}],"paramType":"NUMBER","populationDescription":"Subjects who received study drug","reportingStatus":"POSTED","timeFrame":"Median time-on-study=18.3 weeks","title":"Overall Incidence of Adverse Events","type":"PRIMARY","unitOfMeasure":"Participants"}